Clinical trials recruiting for Gastric cancer
91
Recruiting trials
38
US states with sites
31
Countries
7%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| CEA-targeted CAR-T cells | 4 |
| Bevacizumab | 3 |
| Carboplatin | 3 |
| Pembrolizumab | 3 |
| 5-Fluorouracil | 2 |
| Aldesleukin | 2 |
| Cisplatin | 2 |
| Cyclophosphamide | 2 |
| Fludarabine | 2 |
| Gemcitabine | 2 |
| Irinotecan | 2 |
| Paclitaxel | 2 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Texas | 29 |
| California | 24 |
| Florida | 19 |
| Massachusetts | 16 |
| New York | 14 |
| Tennessee | 13 |
| Virginia | 12 |
| Colorado | 11 |
| Michigan | 11 |
| Ohio | 10 |
| Missouri | 9 |
| Pennsylvania | 9 |
Top cities
Houston, Texas 20Boston, Massachusetts 15Nashville, Tennessee 13Los Angeles, California 12Dallas, Texas 10Fairfax, Virginia 9New York, New York 9San Antonio, Texas 8Detroit, Michigan 7Columbus, Ohio 6
Self-screener
Recruiting trials
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
- A Beta-only IL-2 ImmunoTherapY Study
- A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
- A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
- A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
- A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- A Study of MGC026 in Participants With Advanced Solid Tumors
- A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- A Study of NX-1607 in Adults With Advanced Malignancies
- A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
- A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
- A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
- A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
- A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer
- AB122 Platform Study
- APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
- Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Gastro-intestinal Cancer Patients
- Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
- Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.
- Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
- Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
- CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
- CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors
- COMBO Endoscopy Oropharyngeal Airway Reduces Hypoxia During Sedated Gastrointestinal Endoscopy in Obese Patients: A Multicenter, Randomized, Controlled Clinical Trial
- CONFIRM: Magnetic Resonance Guided Radiation Therapy
- CTNNA1 Familial Expansion Study
- Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- Clinical Application of PET Imaging Targeting CLDN18.2 in Malignant Tumors
- Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
- Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors
- Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
- Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients
- Comprehensive Outcomes for After Cancer Health
- Determining Minimal Residual Disease Using ctDNA Deep Sequencing
- Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
- Distance-Based Exercise to Preserve Function and Prevent Disability
- Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
- Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors
- Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.
- Exploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing
- Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites
- Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
- IDOV-Immune for Advanced Solid Tumors
- IKS014 in Advanced Solid Tumors That Express HER2
- Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers
- Integrated Cancer Repository for Cancer Research
- KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
- Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia
- Lead-212 PSV359 Therapy for Patients With Solid Tumors
- Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
- Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Oral, Fecal and Intratumoral Microbiome Atlas in Colombian Patients With Advanced Solid Tumors Receiving First-Line Immunotherapy
- Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
- Personalized DC Vaccine for Postoperative Cancer
- Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
- Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
- Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients
- Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery
- REVOLUTION Surgery (REVOLUTION Surgery)
- Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors
- Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
- Resilience and Equity in Aging, Cancer, and Health (REACH)
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Samples Procurement for Colorectal Cancer, Gastric Cancer, and Non-malignant Disease
- Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
- Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
- Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
- Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours
- Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
- Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- Surgical TreAtment for Obesity Related Disease and Onco-Metabolic Surgery
- The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III
- Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
- Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
- Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
- [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
- a Single-arm, Single-center, Open Clinical Study
Related conditions
Trials recruiting for Gastric cancer often also study these conditions. Each links to its own recruiting-trial list.
Colorectal cancer 1359Pancreatic cancer 870Lung cancer 2180Breast cancer 2239Esophageal cancer 65Ovarian cancer 118Endometrial cancer 68Prostate cancer 1234Cervical cancer 71Melanoma 487
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Gastric cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.